TARGETING NEW BIOLOGY IN THE TUMOR MICROENVIRONMENT

Pioneering treatment of solid tumors by targeting a novel class of surface protein enabling efficient site-specific delivery of highly potent drugs.

TARGETING NEW BIOLOGY IN THE TUMOR MICROENVIRONMENT

Pioneering treatment of solid tumors by targeting a novel class of surface protein enabling efficient site-specific delivery of highly potent drugs.
OUR VISION

To increase treatment efficacy and periods of remission for cancer patients and, in the future, give people a chance to live cancer-free.

THE ADC PROGRAM

Opportunity in cancer

Antibody-Drug Conjugates are highly potent biopharmaceutical drugs built by attaching a small cytotoxic molecule or another therapeutic agent to an antibody. Using the antibody’s property to target a specific antigen only found on target cells, ADCs deliver the highly potent drugs with a very high specificity to target cells whilst sparing healthy cells. In this way ADCs maximize the efficacy and minimize systemic exposure with associated side effects. ADCs combine the two major advantages of chemotherapy and treatment with biologicals: they are cost-effective and at the same time highly specific with high efficacy and minor systemic effects. Genagon is exploring several ADC assets including the lead drug candidate, GEN201 

https://genagon.com/wp-content/uploads/2021/08/Genagon-bilder-11-1-scaled.jpg
CEO

Moa Fransson, PhD

Genagon has an exciting program with a unique antibody-drug-conjugate which targets tumors and the tumor microenvironment. Our target accumulates only on the surface of cells within the tumor and is rapidly internalized, enabling targeting with low risk of side-effects.

LATEST FROM GENAGONNews

Get in touch

    Get in touch